STOCK TITAN

Lite Strategy (LITS) S-3 Filings

LITS NASDAQ

Ticker history: MEIP became LITS (Lite Strategy, Inc.) on . Earlier news and filings retain their original names and dates. View MEIP history.

Here are the S-3 shelf registrations from Lite Strategy, Inc. (LITS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow LITS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LITS filings page.

Rhea-AI Summary

Lite Strategy, Inc. (LITS) is registering up to 1,889,070 shares of common stock for resale by selling stockholders; they may not sell until the registration statement is effective. The shares comprise 1,322,349 shares issuable upon exercise of GSR Strategies LLC’s pre-funded warrants and 566,721 shares issuable upon exercise of Green Dragon Investments LLC’s warrants, both at $0.0001 per share.

Lite Strategy will receive no proceeds from the selling stockholders’ resales. It may receive up to approximately $132.23 in gross proceeds if the GSR Warrants are exercised in full and $56.67 in gross proceeds if the Advisory Warrants are exercised in full; it expects to use warrant-exercise proceeds for general corporate purposes. Common shares outstanding were 30,407,268 as of September 22, 2026.

Rhea-AI Summary

MEI Pharma, Inc. filed a shelf registration on Form S-3 that describes the company's capitalization and resale mechanics for existing holders. The filing discloses $0.00000002 par value for each of up to 226,000,000 shares of common stock and 100,000 shares of undesignated preferred stock. As of June 30, 2025, 102,513 common shares are issuable upon exercise of warrants at $6.80 per share, 869,168 shares are issuable upon exercise of options with a weighted-average exercise price of $32.85, 920,737 shares are reserved under the 2008 Omnibus Plan, and 169,698 shares are reserved under the 2021 Inducement Plan. The filing lists a range of permitted sale methods for selling stockholders including brokerage, block trades, privately negotiated transactions, option/hedging arrangements, and other lawful methods. It also describes a three-year restriction on certain transfers by any stockholder who becomes an interested stockholder (owner of 15% or more voting stock) unless specific board approvals or exceptions apply. The filing cross-references the company’s Annual Report for the fiscal year ended June 30, 2025 and several Current Reports filed in July–September 2025.